Cargando…
Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report
BACKGROUND: Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to COVID-19 and coagulopathies are a common accompaniment to both T2DM and COVID-19. In addition, patients with COVID-19 are known to develop micro-clots within the lungs. The rapid detection of COVID-19 uses genotypic testing f...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670290/ https://www.ncbi.nlm.nih.gov/pubmed/33203441 http://dx.doi.org/10.1186/s12933-020-01165-7 |
_version_ | 1783610711372464128 |
---|---|
author | Pretorius, Etheresia Venter, Chantelle Laubscher, Gert Jacobus Lourens, Petrus Johannes Steenkamp, Janami Kell, Douglas B. |
author_facet | Pretorius, Etheresia Venter, Chantelle Laubscher, Gert Jacobus Lourens, Petrus Johannes Steenkamp, Janami Kell, Douglas B. |
author_sort | Pretorius, Etheresia |
collection | PubMed |
description | BACKGROUND: Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to COVID-19 and coagulopathies are a common accompaniment to both T2DM and COVID-19. In addition, patients with COVID-19 are known to develop micro-clots within the lungs. The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological test that indicated clotting severity and the extent of clotting pathologies in the individual who was infected or not would be highly desirable. METHODS: Platelet poor plasma (PPP) was collected and frozen. On the day of analysis, PPP samples were thawed and analysed. We show here that microclots can be detected in the native plasma of twenty COVID-19, as well as ten T2DM patients, without the addition of any clotting agent, and in particular that such clots are amyloid in nature as judged by a standard fluorogenic stain. Results were compared to ten healthy age-matched individuals. RESULTS: In COVID-19 plasma these microclots are significantly increased when compared to the levels in T2DM. CONCLUSIONS: This fluorogenic test may provide a rapid and convenient test with 100% sensitivity (P < 0.0001) and is consistent with the recognition that the early detection and prevention of such clotting can have an important role in therapy. |
format | Online Article Text |
id | pubmed-7670290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76702902020-11-18 Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report Pretorius, Etheresia Venter, Chantelle Laubscher, Gert Jacobus Lourens, Petrus Johannes Steenkamp, Janami Kell, Douglas B. Cardiovasc Diabetol Original Investigation BACKGROUND: Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to COVID-19 and coagulopathies are a common accompaniment to both T2DM and COVID-19. In addition, patients with COVID-19 are known to develop micro-clots within the lungs. The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological test that indicated clotting severity and the extent of clotting pathologies in the individual who was infected or not would be highly desirable. METHODS: Platelet poor plasma (PPP) was collected and frozen. On the day of analysis, PPP samples were thawed and analysed. We show here that microclots can be detected in the native plasma of twenty COVID-19, as well as ten T2DM patients, without the addition of any clotting agent, and in particular that such clots are amyloid in nature as judged by a standard fluorogenic stain. Results were compared to ten healthy age-matched individuals. RESULTS: In COVID-19 plasma these microclots are significantly increased when compared to the levels in T2DM. CONCLUSIONS: This fluorogenic test may provide a rapid and convenient test with 100% sensitivity (P < 0.0001) and is consistent with the recognition that the early detection and prevention of such clotting can have an important role in therapy. BioMed Central 2020-11-17 /pmc/articles/PMC7670290/ /pubmed/33203441 http://dx.doi.org/10.1186/s12933-020-01165-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Investigation Pretorius, Etheresia Venter, Chantelle Laubscher, Gert Jacobus Lourens, Petrus Johannes Steenkamp, Janami Kell, Douglas B. Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report |
title | Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report |
title_full | Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report |
title_fullStr | Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report |
title_full_unstemmed | Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report |
title_short | Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report |
title_sort | prevalence of readily detected amyloid blood clots in ‘unclotted’ type 2 diabetes mellitus and covid-19 plasma: a preliminary report |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670290/ https://www.ncbi.nlm.nih.gov/pubmed/33203441 http://dx.doi.org/10.1186/s12933-020-01165-7 |
work_keys_str_mv | AT pretoriusetheresia prevalenceofreadilydetectedamyloidbloodclotsinunclottedtype2diabetesmellitusandcovid19plasmaapreliminaryreport AT venterchantelle prevalenceofreadilydetectedamyloidbloodclotsinunclottedtype2diabetesmellitusandcovid19plasmaapreliminaryreport AT laubschergertjacobus prevalenceofreadilydetectedamyloidbloodclotsinunclottedtype2diabetesmellitusandcovid19plasmaapreliminaryreport AT lourenspetrusjohannes prevalenceofreadilydetectedamyloidbloodclotsinunclottedtype2diabetesmellitusandcovid19plasmaapreliminaryreport AT steenkampjanami prevalenceofreadilydetectedamyloidbloodclotsinunclottedtype2diabetesmellitusandcovid19plasmaapreliminaryreport AT kelldouglasb prevalenceofreadilydetectedamyloidbloodclotsinunclottedtype2diabetesmellitusandcovid19plasmaapreliminaryreport |